---
title: 'SR. RESEARCH ASSOCIATE/ASSOCIATE SCIENTIST, NONCLINICAL DEVELOPMENT at Adicet Bio'
canonical: 'https://feeny.ai/job/sr-research-associate-associate-scientist-nonclinical-development-adicet-bio-m8yk3a1yg86g'
type: 'job'
last_seen: '2026-09-11'
---

# SR. RESEARCH ASSOCIATE/ASSOCIATE SCIENTIST, NONCLINICAL DEVELOPMENT at Adicet Bio

- **Company:** Adicet Bio
- **Location:** Redwood City, CA
- **Compensation:** $108k–$150k
- **Posted:** 2026-07-18
- **Last confirmed live:** 2026-09-11
- **Apply:** https://boards.greenhouse.io/adicettherapeuticsinc/jobs/5189383007?gh_jid=5189383007

## Job description

JOIN US!

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at [https://www.adicetbio.com](https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.adicetbio.com&esheet=54175567&newsitemid=20250108585728&lan=en-US&anchor=https%3A%2F%2Fwww.adicetbio.com&index=1&md5=9d942dbcdb299f0c9fe719a48148cd0e).

RESEARCH ASSOCIATE/ ASSOCIATE SCIENTIST, NONCLINICAL DEVELOPMENT

Key responsibilities:

- Coordinate and execute in vivo and ex vivo nonclinical studies to evaluate Adicet’s immune-cell and gene-therapy platforms, including efficacy, pharmacokinetic/pharmacodynamic, and safety assessments in relevant murine oncology and immunology models.
- Contribute to study design, experimental planning, timeline development, and data-driven decision-making to support program advancement.
- Collaborate and communicate effectively with cross-functional teams and external contract research organizations to coordinate study execution, troubleshoot technical challenges, and ensure study endpoints align with program objectives
- Perform necropsies and process tissues for downstream analyses, including flow cytometry, qPCR/ddPCR, and ELISA, to characterize pharmacologic activity and elucidate mechanisms of action.
- Maintain accurate, complete, and well-organized experimental records in accordance with internal documentation and quality standards.

Qualifications:

- Bachelor’s degree in biological sciences or a related field with 5+ years of relevant R&D experience, or a Master’s degree with 3+ years of experience, preferably in immuno-oncology, within an industry setting.
- Significant experience designing, executing, analyzing, and interpreting in vivo studies using murine xenograft disease models and/or humanized immunology models.
- Demonstrated proficiency administering therapeutic agents and establishing xenograft models through intravenous, intraperitoneal, and subcutaneous routes in mice.
- Strong technical proficiency in blood collection, including submandibular and tail-vein sampling, as well as tissue necropsy and sample processing for flow-cytometry applications.
- Experience with aseptic mammalian cell culture, including the maintenance and preparation of human cancer cell lines for nonclinical in vivo studies.
- Hands-on experience with in vivo bioluminescence and/or fluorescence imaging, including image acquisition and data analysis using IVIS platforms.
- Experience with laboratory techniques such as flow cytometry, ELISA, qPCR/ddPCR, and cytokine bead-based assays is preferred.
- Excellent organizational, communication, data-analysis, and technical-documentation skills.
- Demonstrated ability to work independently, troubleshoot scientific and technical challenges, and contribute innovative solutions.
- Ability to manage multiple priorities and thrive in a fast-paced, collaborative, and supportive research environment.

Adicet fosters a collaborative, high-performing environment by prioritizing in-person engagement. To enhance teamwork and communication, employees are required to be onsite at least three days per week (Tuesday–Thursday mandatory), with some roles requiring full-time onsite presence.

*********************************************** Pay Range $108,000—$150,000 USD

Adicet fosters a collaborative, high-performing environment by prioritizing in-person engagement. To enhance teamwork and communication, employees are required to be onsite at least three days per week (Tuesday–Thursday mandatory), with some roles requiring full-time onsite presence.

At Adicet, our people are our greatest focus. We believe that attracting and retaining the best and brightest is the key to achieving our mission to deliver best-in-class gamma delta T cell therapies for patients fighting autoimmune diseases and cancer.

We offer a competitive compensation package including base salary, annual cash bonus, long-term incentives (equity), Employee Stock Purchase Plan (ESPP) and a 401(k) with ROTH and a 4.5% Company match.

To ensure the wellness of our employees and their loved ones, we offer comprehensive health plans (medical, dental, vision, etc.), Flexible Health and Commuter Spending Accounts (FSA) and a company matched Health Savings Account (HSA). We also offer a life, AD&D, short and long-term disability insurance, and legal, pet, and various other voluntary insurance programs.

We also believe our greatest ideas come when we are refreshed and focused, and we offer generous paid time-off including 13 company holidays, paid end-of-year winter break, vacation, sick time, and paid parental leave.

Adicet is located in a state-of-the-art facility and works to create an incredible office experience with an onsite gym and various other fitness options, onsite parking with electric vehicle charging stations and free shuttle (Caltrain), company-subsidized lunches (delivered onsite daily) and fully stocked breakrooms.

Adicet is committed to creating a diverse environment and is proud to be an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, gender, gender identity or expression, sexual orientation, national origin, genetics, disability, age, or veteran status.

## About Adicet Bio

## Company Overview
- **One-liner**: Adicet Bio is a clinical-stage biotechnology company developing allogeneic, “off-the-shelf” gamma delta T cell therapies for autoimmune diseases and cancer.
- **Entity Type**: Public (Ticker: ACET)
- **Headquarters**: Redwood City, California, USA (with additional offices in Boston, Massachusetts, USA, and Shanghai, China)
- **Founded**: 2015
- **Founders**: Not publicly available (the company originated from the merger of two early-stage biotechs)

## Core Business
- **Primary industries**: Biotechnology, Cell Therapy, Immuno-oncology, Autoimmune Therapeutics
- **Target customers**: B2B – primarily partners with hospitals, clinical research sites, and eventually healthcare providers for treatment administration; ultimately serves patients with cancer and autoimmune diseases
- **Mission statement**: “To deliver best-in-class gamma delta T cell therapies for patients fighting autoimmune diseases & cancer”

## Products & Services
- **Prulacabtagene leucel (prula-cel, formerly ADI-001)**: A first-in-class investigational allogeneic gamma delta 1 CAR T cell therapy, currently in Phase 1 clinical trials for lupus nephritis, systemic lupus erythematosus, systemic sclerosis, idiopathic inflammatory myopathy, stiff person syndrome, ANCA-associated vasculitis, and treatment-refractory rheumatoid arthritis. (Cellular therapy – CAR T, allogeneic/off-the-shelf)
- **Pipeline Programs**: Additional gamma delta T cell therapy programs in discovery and preclinical development for autoimmune diseases and cancer, with a target of one new IND filing every 12–18 months.

## Market Standing
- **Valuation/Market Cap**: Not publicly available for the most recent date (publicly traded, market cap fluctuates; check latest trading data)
- **Key Metric**: Public company; financial results are reported quarterly. As of the most recent filings (Q1 2026 and Full Year 2025), the company is pre-revenue, investing heavily in R&D.
- **Notable Investors/Partners**: Adicet Bio’s investor base includes institutional healthcare investors (details available in SEC filings). The company has presented at major healthcare conferences (e.g., Jefferies Global Healthcare Conference).
- **Growth Signals**: The company is advancing a multi-indication Phase 1 program for prula-cel, targeting seven autoimmune indications simultaneously. They are also building a pipeline with a cadence of one new IND every 12–18 months. The company has active operations across three U.S. sites (Redwood City, Boston) and Shanghai, China.

## Competitive Advantages
- **Gamma Delta 1 T cell platform**: Adicet is a leader in harnessing gamma delta 1 T cells for allogeneic (off-the-shelf) therapy. These cells have an inherent ability to target tissues and kill cells through multiple mechanisms, potentially offering advantages over conventional alpha beta T-cell therapies.
- **Off-the-shelf approach**: By using cells from healthy donors (allogeneic), Adicet’s therapies can be “off-the-shelf” and readily available—potentially faster and more scalable than patient-derived (autologous) CAR T therapies.
- **Dual therapeutic focus**: The company is uniquely positioned with a pipeline targeting both autoimmune diseases (a rapidly growing cell therapy frontier) and oncology, leveraging the same platform.

## Strategic Focus
- **Near-term**: Drive the Phase 1 clinical program for prula-cel across multiple autoimmune indications, with an emphasis on generating proof-of-concept data and advancing toward registrational trials.
- **Pipeline expansion**: Continue to file a new IND every 12–18 months, expanding into new indications with additional gamma delta cell therapy candidates.
- **Platform and manufacturing**: Advance the allogeneic gamma delta platform and manufacturing process to ensure scalability and consistent product quality for future commercial supply.

## Why Work Here
- **Mission-driven**: The company’s core mission is focused on delivering potentially curative therapies for patients with serious autoimmune diseases and cancer, offering a strong sense of purpose.
- **Values**: Culture built on Collaboration, Innovation, Courage, Excellence, Appreciation, and Development. The company explicitly includes “Develop” as a value, emphasizing employee growth.
- **Compensation & Benefits**: Competitive base salary, annual cash bonuses, long-term incentives (stock options), an Employee Stock Purchase Plan (ESPP), and a 401(k) with ROTH option and a 4.5% company match.
- **Work-life & Wellness**: Generous paid time off, including 17 company holidays with an end-of-year shutdown, vacation, sick time, and paid parental leave. Onsite gym, free parking with EV charging, free Caltrain shuttle, daily catered lunches, and fully stocked breakrooms.
- **Learning & Development**: Educational reimbursement program up to $4,000 per calendar year and access to a curated LinkedIn Learning curriculum.
- **Work Model**: Mixed. Positions are listed as on-site at the Redwood City headquarters for most R&D and leadership roles.
- **Team & Environment**: Described as a state-of-the-art facility with a collaborative, highly focused team of scientists and biotech professionals. The company emphasizes attracting and retaining top talent in the cell therapy space.

## Sources
1. [adicetbio.com](https://www.adicetbio.com/)
2. [adicetbio.com/careers](https://www.adicetbio.com/careers/overview/)
3. [adicetbio.com/careers/openings](https://www.adicetbio.com/careers/openings/)
4. [adicetbio.com/about](https://www.adicetbio.com/about/)
5. [investor.adicetbio.com](https://investor.adicetbio.com/investors)

## Other roles at Adicet Bio

- [Manager, Regulatory Affairs](https://feeny.ai/job/manager-regulatory-affairs-adicet-bio-redwood-city-8agd1nr4zgj0) — Redwood City, CA
- [Director/Sr. Director Program Management](https://feeny.ai/job/director-sr-director-program-management-adicet-bio-redwood-city-vzgzddgtmy8q) — Redwood City, CA
- [Director, Quality Assurance Operations](https://feeny.ai/job/director-quality-assurance-operations-adicet-bio-redwood-city-nvk46p4m8tzn) — Redwood City, CA